| TReC
- TRANSLATIONAL
RESEARCH CENTER
CALL
FOR APPLICATIONS
to the DBRM and THRM TReC research project grants 2010
To
download printer-friendly PDF version of the call, click
here.
Background
DBRM
(Developmental Biology for Regenerative Medicine, www.dbrm.se) and THRM
(The Human Regenerative Map, www.thrm.ki.se) are two Linné centers,
supported by the Swedish Research Council. The aim of DBRM is to conduct
internationally leading research in stem cell biology, developmental
biology and regenerative medicine. DBRM consists of 13 research groups,
with expertise in basic science. THRM aims at establishing a map of
cell turnover in the human body in health and disease. To accomplish
this, THRM has devised a novel strategy based on the resetting of 14C
in the atmosphere following nuclear bomb tests to retrospectively establish
the birth date of cells.
Both
DBRM and THRM have the mission to strengthen the links to clinical science
at the Karolinska Institute (KI). To this end, DBRM and THRM have initiated
a Translational Research Center (TReC), to facilitate the interactions
between basic and clinical science. The Scientific Board at TReC consists
of Drs. Ernest Arenas, Jonas Frisén, Katarina Le Blanc and Urban
Lendahl. In addition to organizing courses, workshops and symposia to
bring basic and clinical scientists at KI closer together, a mission
for TReC is to provide funding for research projects spanning basic
and clinical science.
TReC
Research Project grants
TReC
will provide approximately 1000 kSEK funding annually to projects that
have a combined basic and clinical aspect in the areas of stem cell
biology, developmental biology or regenerative medicine. The underlying
idea is to i) bring questions addressed in DBRM and THRM closer to the
clinical setting, or conversely, ii) provide cell or molecular biology
expertise to questions addressed in the clinic. The following guidelines
apply for the project applications:
1.
The application should be a joint application from a PI in DBRM or THRM
and a scientist at KI outside DBRM and THRM, working on more clinically
oriented problems. Applications should address important problems in
stem cell biology, developmental biology or regenerative medicine.
2.
It is preferable that the application has a sufficiently strong clinical
component to also be in principal appropriate for funding through the
ALF system (although there is no strict requirement for simultaneously
applying for ALF grants). The rationale for this is to make the TReC
projects distinct from already ongoing, more basic research-oriented,
projects in DBRM and THRM.
3.
The application should not exceed 3 A4 pages (single spacing, font 12,
including references and figures). Applications should be sent in in
full, there is no pre-proposal procedure. Applications should be sent
as single PDF files to Ola.Hermanson@ki.se. A one-page CV for each PI,
including a list of five relevant publications, should also be enclosed.
There is no requirement for a detailed budget, only for an estimate
of how the funding will be distributed between the DBRM partner and
the clinical scientist.
4.
Applications will be judged for scientific merit by the TReC Scientific
Board (see above), and if deemed necessary by the Board, for example
because of conflicts of interest, by ad hoc outside experts.
5.
We expect that up to five applications per year can be funded, which
means that successful applications can be funded in the range of 200-300
kSEK/year. The funding period is one year, and the application should
be written to reflect this time period.
The
deadline for applications is September 10, 2010. Further information
can be obtained from Ola Hermanson (Ola.Hermanson@ki.se).
About
the DBRM Translational Research Center (TReC)
The
Translation Research Center (TReC) is an important component of DBRM,
serving as a means for rapid and efficient flux of information between
basic and clinical research. TReC will serve as a mechanism for rapid
testing in advanced animal models and other clinically relevant settings
of hypotheses and reagents based on data generated by basic research.
Conversely, empirical observations made in the clinic can be explored
in depth by cell and molecular biology-based approaches in basic science.
TReC
has a Scientficic Board, which consists of Ernest Arenas, Outi Hovatta,
Katarina Le Blanc and Urban Lendahl. In addition to organizing courses,
workshops and symposia to bring basic and clinical scientists at KI
closer together, an important mission for TReC is also to provide funding
for research projects spanning basic and clinical science. The first
calls for applications to this program were announced Spring 2007 and
2008 to be repeated annually.
Call for applications to the DBRM TReC
research project
grants 2008
This
call is now closed.
Background
DBRM (Developmental Biology for Regenerative Medicine, www.dbrm.se)
is a Linné center, supported by the Swedish Research Council.
The aim of DBRM is to conduct internationally leading research in stem
cell biology, developmental biology and regenerative medicine. DBRM
consists of 13 research groups, with expertise in basic science, and
one mission of DBRM is to strengthen the links to clinical science at
the Karolinska Institute (KI). To this end, DBRM has initiated a Translational
Research Center (TReC), to facilitate the interactions between basic
and clinical science. The Scientific Board at TReC consists of Drs.
Ernest Arenas, Outi Hovatta, Katarina Le Blanc and Urban Lendahl. In
addition to organizing courses, workshops and symposia to bring basic
and clinical scientists at KI closer together, a mission for TReC is
to provide funding for research projects spanning basic and clinical
science.
TReC Research Project grants
TReC will provide approximately 500 kSEK funding annually to projects
that have a combined basic and clinical aspect in the areas of stem
cell biology, developmental biology or regenerative medicine. The underlying
idea is to i) bring questions addressed in DBRM closer to the clinical
setting, or conversely, ii) provide cell or molecular biology expertise
to questions addressed in the clinic. The following guidelines apply
for the project applications:
1. The application should be a joint application from a PI in DBRM and
a scientist at KI outside DBRM, working on more clinically oriented
problems. Applications should address important problems in stem cell
biology, developmental biology or regenerative medicine.
2. It is preferable that the application has a sufficiently strong clinical
component to also be in principalappropriate for funding through the
ALF system (although there is no strict requirement for simultaneously
applying for ALF grants). The rationale for this is to make the TReC
projects distinct from already ongoing, more basic research-oriented,
projects in DBRM.
3. The application should not exceed 3 A4 pages (single spacing, font
12, including references and figures). Applications should be sent in
in full, there is no pre-proposal procedure. Applications should be
sent as single PDF files to Urban.Lendahl@ki.se. There is no requirement
for a detailed budget, only for an estimate of how the funding will
be distributed between the DBRM partner and the clinical scientist.
4. Applications will be judged for scientific merit by the TReC Scientific
Board (see above), and if deemed necessary by the Board, by ad hoc outside
experts.
5. We expect that up to five applications per year can be funded, which
means that successful applications can be funded in the range of 100-200
kSEK/year. The funding period is one year, and the application should
be written to reflect this time period.
6. The deadline for applications is August 15, 2008. Further
information can be obtained from Urban Lendahl (Urban.Lendahl@ki.se).
Call
for applications to the DBRM TReC research project grants 2007
This
call is now closed.
Background
DBRM (Developmental Biology for Regenerative Medicine,
www.dbrm.se) is a Linné center, supported by the Swedish Research
Council. The aim of DBRM is to conduct internationally leading research
in stem cell biology, developmental biology and regenerative medicine.
DBRM consists of 13 research groups, with expertise in basic science,
and one mission of DBRM is to strengthen the links to clinical science
at the Karolinska Institute (KI). To this end, DBRM has initiated a
Translational Research Center (TReC), to facilitate the interactions
between basic and clinical science. The Scientific Board at TReC consists
of Drs. Ernest Arenas, Outi Hovatta, Katarina Le Blanc and Urban Lendahl.
In addition to organizing courses, workshops and symposia to bring basic
and clinical scientists at KI closer together, a mission for TReC is
to provide funding for research projects spanning basic and clinical
science.
TReC
Research Project grants
TReC will provide approximately 500 kSEK funding annually
to projects that have a combined basic and clinical aspect in the areas
of stem cell biology, developmental biology or regenerative medicine.
The underlying idea is to i) bring questions addressed in DBRM closer
to the clinical setting, or conversely, ii) provide cell or molecular
biology expertise to questions addressed in the clinic. The following
guidelines apply for the project applications:
1.
The application should be a joint application from a PI in DBRM and
a scientist at KI outside DBRM, working on more clinically oriented
problems. Applications should address important problems in stem cell
biology, developmental biology or regenerative medicine.
2.
It is preferable that the application has a sufficiently strong clinical
component to also be in principal appropriate for funding through the
ALF system (although there is no strict requirement for simultaneously
applying for ALF grants). The rationale for this is to make the TReC
projects distinct from already ongoing, more basic research-oriented,
projects in DBRM.
3.
The application should not exceed 3 A4 pages (single spacing, font 12,
including references and figures). Applications should be sent in in
full, there is no pre-proposal procedure. Applications should be sent
as single PDF files to Urban.Lendahl@ki.se. There is no requirement
for a detailed budget, only for an estimate of how the funding will
be distributed between the DBRM partner and the clinical scientist.
4.
Applications will be judged for scientific merit by the TReC Scientific
Board (see above), and if deemed necessary by the Board, by ad hoc outside
experts.
5.
We expect that up to five applications per year can be funded, which
means that successful applications can be funded in the range of 100-200
kSEK/year. The funding period is one year, and the application should
be written to reflect this time period.
6.
The deadline for applications is August 30, 2007. Further information
can be obtained from Urban Lendahl (Urban.Lendahl@ki.se).
|